tbuckley/cabot-search huggingface dataset:
Horizontal Transmission of Feline Leukemia Virus Under Experimental Conditions2
Authors: Edward A. Hoover, Richard G. Olsen, William D. Hardy, Joseph P. Schaller
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Horizontal Transmission of Feline Leukemia Virus Under Experimental Conditions Get access Edward A. Hoover, Edward A. Hoover Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard G. Olsen, Richard G. Olsen Search for other works by this author on: Oxford Academic PubMed Google Scholar William D. Hardy, Jr., William D. Hardy, Jr. Search for other works by this author on: Oxford Academic PubMed Google Scholar Joseph P. Schaller Joseph P. Schaller Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 2, February 1977, Pages 443–444, https://doi.org/10.1093/jnci/58.2.443 Published: 01 February 1977 Article history Received: 23 April 1976 Accepted: 12 July 1976 Published: 01 February 1977
Late new morbidity in survivors of adolescent and young-adulthood brain tumors in Finland: a registry-based study
Authors: Mirja Erika Gunn, Nea Malila, Tuire Lähdesmäki, Mikko Arola, Marika Grönroos, Jaakko Matomäki, Päivi Maria Lähteenmäki
Journal: Neuro-Oncology (2015)

Brain tumors (BTs) in adolescence and young adulthood (AYA) differ from those in childhood or late adulthood. However, research concerning late effects in this particular survivor group is limited. This study evaluates late morbidity of survivors diagnosed in AYAs. We identified from the Finnish Cancer Registry all survivors diagnosed with BT at the ages 16–24 years between 1970 and 2004 (N = 315) and used data from the Hospital Discharge Registry to evaluate their late (≥5 y after diagnosis) morbidity requiring treatment in a specialized health care setting. A sibling cohort of BT patients diagnosed before the age of 25 years was used as a comparison cohort (N = 3615). The AYA BT survivors had an increased risk for late-appearing endocrine diseases (HR, 2.9; 95% CI, 1.1–8.0), psychiatric disorders (HR, 2.0; 95% CI, 1.2–3.2), diseases of the nervous system (HR, 9; 95% CI, 6.6–14.0), disorders of vision/hearing loss (HR, 3.6; 95% CI, 1.5–8.5), diseases of the circulatory system (HR, 4.9; 95% CI, 2.9–8.1), and diseases of the kidney (HR, 5.9; 95% CI, 2.5–14.1). Survivors with irradiation had an increased risk for diseases of the nervous system compared with non-irradiated survivors (HR, 3.3; 95% CI, 1.8–6.2). The cumulative prevalence for most of the diagnoses remained significantly increased for survivors even 20 years after cancer diagnosis. The AYA BT survivors have an increased risk of morbidity for multiple new outcomes for ≥5 years after their primary diagnosis. This emphasizes the need for structured late-effect follow-up for this patient group.
Assessment of multiple markers for association with response rate (RR) and failure-free survival (FFS) in patients with advanced colorectal cancer (CRC) treated with chemotherapy in the MRC CR08 (FOCUS) randomized trial
Authors: J. W. Adlard, S. D. Richman, P. Royston, J. M. Allan, A. Meade, M. Parmar, P. Selby, P. Quirke, M. T. Seymour
Journal: Journal of Clinical Oncology (2004)

9506 Background: We have assessed potential prognostic and predictive markers of response to fluorouracil (FU) in advanced CRC patients randomized 4:1:1 to FU alone, FU+oxaliplatin, or FU+irinotecan. Methods: Pathology specimens were retrieved from 846 patients in the FOCUS trial. 85% were from the primary site. Normal and tumor DNA and RNA were extracted and tissue microarrays were made for immunohistochemistry (IHC). The following factors were assessed for effect on FFS and RR to first-line therapy: age; performance status; primary site; liver metastases; serum ALP; grade; mucoid status; IHC for hMLH1, hMSH2, P53, SMAD4, dUTPase, DPD, thymidine phosphorylase (TP), thymidylate synthase (TS); TS mRNA expression; DNA polymorphisms in TS (TSER, TS1494), hMLH1 (–93 G→A), MTHFR (677 C→T). Results: Overall RR and median FFS to first-line therapy were 42% and 8 months respectively. The table shows markers with significant relationships to RR and FFS. Together markers explained 6% of the variability in outcome, with the IHC/histology markers contributing most. DNA polymorphisms showed no clear association with outcomes. Similar associations of marker status were found for patients treated with FU alone or FU+oxaliplatin/irinotecan. Using logistic regression, a predictive algorithm could separate tumors into groups with RR from 15% to 50% for treatment with FU alone and 25% to 70% for treatment with FU+oxaliplatin/irinotecan. Conclusions: Significant differences in RR have been identified for mucoid status, TS IHC and dUTPase IHC scores allowing development of a predictive algorithm for response to FU-containing chemotherapy. Associations with modest differences in FFS were also identified. Ongoing work is looking at markers specific for oxaliplatin or irinotecan benefit. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
Authors: Caroline Happold, Thierry Gorlia, Olivier Chinot, Mark R. Gilbert, L. Burt Nabors, Wolfgang Wick, Stephanie L. Pugh, Monika Hegi, Timothy Cloughesy, Patrick Roth, David A. Reardon, James R. Perry, Minesh P. Mehta, Roger Stupp, Michael Weller
Journal: Journal of Clinical Oncology (2016)

Symptomatic epilepsy is a common complication of glioblastoma and requires pharmacotherapy. Several uncontrolled retrospective case series and a post hoc analysis of the registration trial for temozolomide indicated an association between valproic acid (VPA) use and improved survival outcomes in patients with newly diagnosed glioblastoma.To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741). Progression-free survival (PFS) and overall survival (OS) were compared between: (1) any VPA use and no VPA use at baseline or (2) VPA use both at start of and still after chemoradiotherapy. Results of Cox regression models stratified by trial and adjusted for baseline prognostic factors were analyzed. The same analyses were performed with levetiracetam (LEV).VPA use at start of chemoradiotherapy was not associated with improved PFS or OS compared with all other patients pooled (PFS: hazard ratio [HR], 0.91; 95% CI, 0.77 to 1.07; P = .241; OS: HR, 0.96; 95% CI, 0.80 to 1.15; P = .633). Furthermore, PFS and OS of patients taking VPA both at start of and still after chemoradiotherapy were not different from those without antiepileptic drug use at both time points (PFS: HR, 0.92; 95% CI, 0.74 to 1.15; P = .467; OS: HR, 1.10; 95% CI, 0.86 to 1.40; P = .440). Similarly, no association with improved outcomes was observed for LEV use.The results of this analysis do not justify the use of VPA or LEV for reasons other than seizure control in patients with newly diagnosed glioblastoma outside clinical trials.
<i>Notes from the Field</i>: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention — Eastern and Southern Africa, 2012–2015
Authors: Jonathan M. Grund, Carlos Toledo, Stephanie M. Davis, Renee Ridzon, Edna Moturi, Heather Scobie, Boubker Naouri, Jason B. Reed, Emmanuel Njeuhmeli, Anne G. Thomas, Francis Ndwiga Benson, Martin W. Sirengo, Leon Ngeruka Muyenzi, Gissenge J.I. Lija, John H. Rogers, Salli Mwanasalli, Elijah Odoyo-June, Nafuna Wamai, Geoffrey Kabuye, James Exnobert Zulu, Jane Ruth Aceng, Naomi Bock
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Voluntary medical male circumcision (VMMC) decreases the risk for female-to-male HIV transmission by approximately 60%, and the President's Emergency Plan for AIDS Relief (PEPFAR) is supporting the scale-up of VMMC for adolescent and adult males in countries with high prevalence of human immunodeficiency virus (HIV) and low coverage of male circumcision. As of September 2015, PEPFAR has supported approximately 8.9 million VMMCs.
Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction
Authors: JR Downing, SA Shurtleff, M Zielenska, AM Curcio-Brint, FG Behm, DR Head, JT Sandlund, DD Weisenburger, AE Kossakowska, P Thorner
Journal: Blood (1995)
Studies on the relationship between the catecholamine distribution in the atrium and the specific granules present in atrial muscle cells: 1. Isolation of a purified specific granule subfraction
Authors: A. J. D. BOLD, S. A. BENCOSME
Journal: Cardiovascular Research (1973)

Electron microscopy of mammalian atrial muscle cells reveals a population of specific granules suggesting that the atrial muscle cells may have a secretory function. As a preliminary step towards the investigation of the function of the specific granules, a procedure was designed to isolate these particles by differential and density gradient centrifugation of rat atrial homogenates. The specific granule preparation obtained showed a considerable degree of purification with respect to marker enzymes. The isolated granules retained their in situ fine structure and staining properties.
비알코올지방간을 가진 한국 남성에서 ALT 증가와 혈중 adiponectin치의 연관성
Authors: 이용수 ( Yong Su Lee ), 조용균 ( Yong Kyun Cho ), 배지철 ( Ji Cheul Pae ), 오세용 ( Se Yong Oh ), 강문수 ( Mun Su Kang ), 박정호 ( Jung Ho Park ), 김홍주 ( Hong Joo Kim ), 박동일 ( Dong Il Park ), 손정일 ( Chong Il Sohn ), 전우규 ( Woo Kyu Jeon ), 김병익 ( Byung Ik Kim ), 이원영
Journal: Clinical and Molecular Hepatology (2006)

목적: 비알코올지방간질환(nonalcoholic fatty liver disease, NAFLD)은 단순 지방증과 지방간염을 포함하며, 간경변증으로 진행할 수 있다. 최근 지방세포에서 분비되는 adiponectin, resistin, leptin 같은 adipokines과 비알코올지방간의 위험 인자로 알려진 비만, 당뇨병과 고지혈증 등 대사증후군 사이에는 밀접한 관...
Symptom prevalence of cancer patients dying with and without palliative sedation at a specialized unit for palliative care in a cancer center
Authors: L. Van Zuylen, L. Van der Wijk, H. Van Veluw, A. Van der Heide, C. C. Van der Rijt
Journal: Journal of Clinical Oncology (2006)

8576 Background: Palliative sedation (PS) may be needed in dying cancer patients to achieve acceptable symptom control. Little is known about the differences between sedated and non-sedated patients. To determine characteristics of sedated and non-sedated patients, we performed a retrospective study in patients who died during admission to the palliative care unit (PCU) of the cancer center. Methods: From October 2001 until October 2005, 157 out of 753 admitted patients died at the PCU. The medical and nursing records were studied with respect to patient characteristics and the symptom profile at admission and during the last 72 hrs of life. Results: Of all deceased patients, 68 (43%) were sedated prior to death. The median duration of the sedation was 19 hrs (range 0.7–125). No differences between sedated and non-sedated patients were found in age (median 58 years, range 25–89) and time between admission and death (7 days, 1–38). The primary tumor sites were mostly lung (22.1%), GI tract (20.6%), and breast (16.2%) in the sedated patients, and breast (24.7%), lung (13.5%) and urogenital tract (11.2%) in the non-sedated patients. The symptoms at admission were mainly pain (82%), constipation (43%) and dyspnea (31%) and did not differ between both groups. Prior to the start of PS, sedated patients more often had delirium and dyspnea as compared to non-sedated patients at similar times before death. Conclusions: PS was needed to control symptoms for somewhat less than half of the patients dying at the PCU. Pain was a main reason for admission in both groups, but dyspnea and delirium were more common in sedated patients during admission. [Table: see text] No significant financial relationships to disclose.
Redesigning Care for Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Authors: Arthur Reshad Garan, Ajay Kirtane, Hiroo Takayama
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Well-Demarcated, Scaly Plaques
Authors: Emily C. Milam, Shane A. Meehan, Sarika Ramachandran
Journal: JAMA (2016)

A 46-year-old woman presented with well-demarcated erythematous scaly plaques, with central clearing, on her chest, back, flanks, and groin. She reported that the eruption worsens with warmer weather but reported no other pain or rash. What would you do next?
A prospective randomised study on narrow-band imaging versus conventional colonoscopy for adenoma detection: does narrow-band imaging induce a learning effect?
Authors: A Adler, H Pohl, I S Papanikolaou, H Abou-Rebyeh, G Schachschal, W Veltzke-Schlieker, A C Khalifa, E Setka, M Koch, B Wiedenmann, T Rosch
Journal: Gut (2007)

Colonoscopy is an established method of colorectal cancer screening, but has an adenoma miss rate of 10-20%. Detection rates are expected to improve with optimised visualisation methods. This prospective randomised study evaluated narrow-band imaging (NBI), a new technique that may enhance image contrast in colon adenoma detection.Eligible patients presenting for diagnostic colonoscopy were randomly assigned to undergo wide-angle colonoscopy using either conventional high-resolution imaging or NBI during instrument withdrawal. The primary outcome parameter was the difference in the adenoma detection rate between the two techniques.A total of 401 patients were included (mean age 59.4 years, 52.6% men). Adenomas were detected more frequently in the NBI group (23%) than in the control group (17%) with a number of 17 colonoscopies needed to find one additional adenoma patient; however, the difference was not statistically significant (p = 0.129). When the two techniques were compared in consecutive subgroups of 100 study patients, adenoma rates in the NBI group remained fairly stable, whereas these rates steadily increased in the control group (8%, 15%, 17%, and 26.5%, respectively). Significant differences in the first 100 cases (26.5% versus 8%; p = 0.02) could not be maintained in the last 100 cases (25.5% versus 26.5%, p = 0.91).The increased adenoma detection rate means of NBI colonoscopy were statistically not significant. It remains speculative as to whether the increasing adenoma rate in the conventional group may have been caused by a training effect of better polyp recognition on NBI.
Clinical correlates of <i>HER2</i> amplification: A multivariable analysis
Authors: J. P. Crowe, G. T. Budd, R. J. Patrick, L. A. Rybicki, R. R. Tubbs, D. Hicks
Journal: Journal of Clinical Oncology (2005)

696 Background: Profiling the status of the HER2 gene has become an increasingly important factor for patients with breast cancer. The purpose of this analysis was to describe clinical correlates for HER2 amplification in patients with infiltrating ductal carcinoma (INDC). Methods: Data were collected prospectively in our institutional review board approved patient registry for patients diagnosed with INDC. Measurement of human epidermal growth factor 2 (HER2) was performed on all tumors using fluorescence in-situ hybridization. Variables analyzed were race; age at diagnosis; hormone receptor status; incidence of bilateral or multifocal tumors; TNM Stage; the presence of angiolymphatic invasion; the type (if any) of ductal carcinoma in-situ (DCIS); Scarff-Bloom-Richardson grade (SBR); and HER2 amplification (HER2+). Logistic regression analysis was used to identify multivariable correlates of HER2+, and model-based probabilities were calculated. Results: Data were available for 1083 patients, including 944 (87%) who were self-described as white and 139 who were black. The median age at diagnosis was 58 years (range 23–94 years). A majority of tumors (74%) were hormone receptor positive, unilateral (95%) and unifocal (90%), TNM Stage I or II (85%), and without associated angiolymphatic invasion (72%). Type DCIS was available for 1023 tumors, including 93 (9%) defined as comedo only; 181 (18%) comedo mixed with any other type; 288 (28%) without DCIS; and 461 (45%) with any non-comedo type. SBR was available for 1045 tumors, including 254 (24%) grade 1; 378 (36%) grade 2; and 413 (40%) grade 3. Of 1083 tumors, 211 (19.5%) were HER2+. The final data model resulted in 3 variables (age, SBR, and type DCIS), and indicated younger patients were more likely to have HER+ tumors; likelihood of HER+ increased as SBR increased, and HER+ was most likely in tumors with comedo DCIS. For example, a 90-year old patient without associated DCIS had a 3.3% chance of HER+ compared to a 55.2% chance for a 30-year old with comedo DCIS. Conclusions: A multivariable analysis indicated that younger patients were more likely to have tumors that were HER2+, and that the likelihood of HER+ increased as SBR increased and in tumors with associated comedo DCIS. No significant financial relationships to disclose.
Dietary Fucose Helps Attenuate Metastatic Melanoma in Mice
Authors: Tracy Hampton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic characterization of the association between asthma and obesity. Relationship with severity and asthma control
Authors: Zoran Stojanovic, Astrid Crespo, Juan Roldan, Vicente Plaza, Sonia Ragull, Joan Anton Lloret, G. Casolivas, A. Reig, Josep Morera Prat, Carlos Martinez Rivera
Journal: European Respiratory Journal (2011)

Introduction: The inflammatory way of the TNF-alfa could be a mutual way of the asthma-obesity phenotype.

Objective: To evaluate if the presence of polymorphisms at the promoter of gene TNF-alfa-308 G/A is related with an asthma-obesity phenotype and determines the severity of the disease measured by the number of exacerbations.

Methods: We included blood samples of 48 asthmatics. To determine the presence of polymorphism -308G/A in the promoter region of TNF-alpha gene, we performed the technique of chain reaction (PCR) followed by the generation of restriction fragments and digestion of the amplified product. The product of digestion was visualized in a gel of 3% agarose. This allowed us to distinguish native allele TNF-1 with 2 fragments of restriction, 87pb and 20 bp and polymorphic allele TNF-2 of 107 bp.

Results: The average age 28±14,6 years, 83% men. Genotype distribution was: AA (4%), AG (23%) y GG (73%). No statistically significant differences were found between different alleles and IMC. When we analyzed the evolution of disease considering the number of exacerbations we observed that presence of allele A determines greater number of exacerbations during the year (p=0.02).

![Figure][1] 



Conclusions: The presence of the allele A has been associated with a worse prognosis as measured by the number of exacerbations, which could be explained by an increase in promoter activity and TNF secretion.

 [1]: pending:yes
Comparative Subacute Toxicity of Retinyl Acetate and Three Synthetic Retinamides in Swiss Mice<xref ref-type="fn" rid="FN2">2</xref>
Authors: E J Hixson, E P Denine
Journal: JNCI Journal of the National Cancer Institute (1979)

Young adult male and female Swiss mice were treated once daily for 21 days with graded dosages of retinyl acetate (RAC) or one of three synthetic retinoids: N-ethylretinamide (EA), N-(2-hydroxyethyl)retinamIde (HEA), and N-(4-hydroxyphenyl)retinamlde (HPA), all derived from all-trans-retinoic acid. When the mice were killed, blood was obtained for hematology and clinical chemistry studies, and tissues were collected and fixed for histopathologic evaluation. Decreases in erythrocyte counts, hemoglobin concentration, and hematocrit and increases in reticulocyte counts were frequent in mice treated ip but not orally. Increases in granulocyte counts were seen in some retinold-treated groups. Changes in clinical chemistry tests included decreases in plasma glucose, total protein, albumin, and globulin concentration and increases in plasma glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase activity and in bllirubin and lnorganic phosphorus concentrations. Diagnostic X-rays indicated a dose-related incidence of fractures in mice that received RAC ip or orally but not in other treated groups. Degeneration and necrosis of hepatocytes were observed in mice receiving ip EA or ip or oral HEA except at the lowest dosages but not in mice receiving RAC or HPA. On the basis of the dosages used and the clinical and histopathologic evaluation, RAC was the most toxic after ip administration (RAC>HEA>EA>HPA) and after oral administration (RAC≈HEA>EA>HPA). Depending on the structure of the substituent, toxicity of synthetic-substituted retinamides may be less than that of a retinyl ester.